Home

slack Wonder sunflower annkristin heine Decent Starting point calf

BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed  cells | BMC Biology | Full Text
BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells | BMC Biology | Full Text

Tückischen Blutkrebs effektiv bekämpfen - Centrum für Integrierte Onkologie
Tückischen Blutkrebs effektiv bekämpfen - Centrum für Integrierte Onkologie

Total marrow irradiation versus total body irradiation using  intensity-modulated helical tomotherapy,Journal of Cancer Research and  Clinical Oncology - X-MOL
Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy,Journal of Cancer Research and Clinical Oncology - X-MOL

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and  Function | PLOS ONE
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function | PLOS ONE

Immunotherapy as an advance in cancer medicine - Innovations Report
Immunotherapy as an advance in cancer medicine - Innovations Report

Implementing combinatorial immunotherapeutic regimens against cancer
Implementing combinatorial immunotherapeutic regimens against cancer

Annkristin HEINE | Medical Doctor | Professor | University of Bonn -  Medical Center, Bonn | Haematology Oncology | Research profile
Annkristin HEINE | Medical Doctor | Professor | University of Bonn - Medical Center, Bonn | Haematology Oncology | Research profile

Researchers release the brakes on the immune | EurekAlert!
Researchers release the brakes on the immune | EurekAlert!

CIO Bonn - Lymphomzentrum
CIO Bonn - Lymphomzentrum

UKB NewsRoom | Annkristin Heine
UKB NewsRoom | Annkristin Heine

Tumor rejection in Cblb−/− mice depends on IL-9 and Th9 cells | Journal for  ImmunoTherapy of Cancer
Tumor rejection in Cblb−/− mice depends on IL-9 and Th9 cells | Journal for ImmunoTherapy of Cancer

Volume 21, Issue 3, Pages (October 2017) - ppt download
Volume 21, Issue 3, Pages (October 2017) - ppt download

Frontiers | Case report: Complete response to pembrolizumab in a liver  metastatic colon adenocarcinoma patient with a novel likely pathogenic  germline MSH2 mutation
Frontiers | Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation

Prof. Dr. med. Annkristin Heine - Hämatologie und Onkologie des  Universitätsklinikums Bonn
Prof. Dr. med. Annkristin Heine - Hämatologie und Onkologie des Universitätsklinikums Bonn

AG Heine - Hämatologie und Onkologie des Universitätsklinikums Bonn
AG Heine - Hämatologie und Onkologie des Universitätsklinikums Bonn

Annkristin HEINE | Medical Doctor | Professor | University of Bonn -  Medical Center, Bonn | Haematology Oncology | Research profile
Annkristin HEINE | Medical Doctor | Professor | University of Bonn - Medical Center, Bonn | Haematology Oncology | Research profile

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and  Function | PLOS ONE
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function | PLOS ONE

Bjørn Heine Strand - NIPH
Bjørn Heine Strand - NIPH

Medicine®
Medicine®

Café Kinderwagen: ein Angebot für Groß und Klein | Spökenkieker - Ihr  regionales Anzeigenmagazin
Café Kinderwagen: ein Angebot für Groß und Klein | Spökenkieker - Ihr regionales Anzeigenmagazin

G-quadruplexes: a promising target for cancer therapy | Molecular Cancer |  Full Text
G-quadruplexes: a promising target for cancer therapy | Molecular Cancer | Full Text

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and  Function
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function

Cardiac MRI Depicts Immune Checkpoint Inhibitor–induced Myocarditis: A  Prospective Study
Cardiac MRI Depicts Immune Checkpoint Inhibitor–induced Myocarditis: A Prospective Study

UKB NewsRoom | Erfolg bei Ausschreibung „Advanced Clinician Scientist“
UKB NewsRoom | Erfolg bei Ausschreibung „Advanced Clinician Scientist“

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic  cells | SpringerLink
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells | SpringerLink

Frontiers | Red blood cell transfusions impact response rates to  immunotherapy in patients with solid malignant tumors
Frontiers | Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors